Home › NCT07112287

Germline Testing for Predisposition to Myeloid Malignancies

MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age of 18 years or older
* Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening.
* Ability to understand and provide a signed and completed consent document in English.

Exclusion Criteria:

* Participants who cannot safely undergo clinically indicated skin biopsy as adjudicated by the study team.
* Participants who have previously undergone germline genetic testing for predisposition to myeloid malignancies

About the study

The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.

What is being tested

• MyeloGen Gene Panel (device)

Sponsor: Christopher Reilly · Participants: 200 · Started: Nov 10, 2025

Contact the study team

• Christopher R Reilly, MD · Phone: 407-443-6243

Official record on ClinicalTrials.gov — NCT07112287

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.